pages 27-28 of the specification has been divided into Figures 1A and 1B. With these changes Applicant believes that he has complied with the Examiners concerns. See attached amended drawings.

In the Claims:

5. The receptor protein H4-1BB produced by

- a) inserting the cDNA of H4-1BB into an appropriate expression vector,
- b) transfecting said expression vector into an appropriate transfection host,
- c) growing said transfected hosts in appropriate culture media and
- d) purifying the receptor protein from said culture media.

(Amended) An isolated protein having the amino acid sequence shown in SEQ. ID. NO. 2

21. (Amended) A purified <u>fragment of the [human] H4-lBB</u> polypeptide comprising the N-terminal amino acid sequence Leu-Gln-Asp-Pro-Cys-Ser-Asn-Cys-Pro-Ala-Gly-Thr-.

22. (Amended) A purified H4-IBB according to claim 21, comprising an amino acid sequence selected from the group consisting of amino acids 24-255 of SEQ ID NO:2 and amino acids 24-186 of SEQ ID NO:2.

24. (Amended) A purified soluble [human] H4-1BB polypeptide, wherein said polypeptide comprises the extracellular domain of [human] H4-1BB (amino acids 24-186 of SEQ ID NO:2).

25. (Amended) A pharmaceutical composition comprising a soluble [human] H4-1BB of claim 21 in admixture with a suitable diluent, carrier, or excipient.

3